These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 16178803)
1. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes. Lindberg EH Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803 [TBL] [Abstract][Full Text] [Related]
2. Physician Education: Myelodysplastic Syndrome. Yoshida Y Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004 [TBL] [Abstract][Full Text] [Related]
3. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Nimer SD J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711 [TBL] [Abstract][Full Text] [Related]
4. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). List AF Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Stahl M; Zeidan AM Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601 [TBL] [Abstract][Full Text] [Related]
6. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. List AF; Baker AF; Green S; Bellamy W Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661 [TBL] [Abstract][Full Text] [Related]
7. Supportive care, growth factors, and new therapies in myelodysplastic syndromes. Hellström-Lindberg E; Malcovati L Blood Rev; 2008 Mar; 22(2):75-91. PubMed ID: 18068281 [TBL] [Abstract][Full Text] [Related]
13. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965 [TBL] [Abstract][Full Text] [Related]
14. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies]. Aul C; Giagounidis A; Germing U; Ganser A Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275 [TBL] [Abstract][Full Text] [Related]
15. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. Zavras PD; Sinanidis I; Tsakiroglou P; Karantanos T Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902450 [TBL] [Abstract][Full Text] [Related]
16. Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes. Tehranchi R Med Oncol; 2006; 23(1):37-49. PubMed ID: 16645228 [TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes: moving towards personalized management. Hellström-Lindberg E; Tobiasson M; Greenberg P Haematologica; 2020 Jul; 105(7):1765-1779. PubMed ID: 32439724 [TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes: the pediatric point of view. Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722 [TBL] [Abstract][Full Text] [Related]
20. Mutations of myelodysplastic syndromes (MDS): An update. Ganguly BB; Kadam NN Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]